Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma

Sequential therapy with alternating short courses of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R‐FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma

“…The prolonged PFS and the safe toxicity profile led to an OS rate of 100% at 10 years in the untreated group and 70% in the pretreated group. These results confirm previous positive experiences with regimens that alternate purine analogs and alkylating agents in FL (Ai et al , ). The recently superior PFS results reported with the rituximab‐bendamustine regimen (which combines both alkylating and antimetabolite properties) compared to R‐CHOP (Rummel et al , ) are also in line with these findings.…”